News
MIST
2.170
+6.90%
0.140
Milestone Pharmaceuticals GAAP EPS of -$0.19
Seeking Alpha · 1d ago
Based on the provided financial report, the title of the article is: "Milestone Pharmaceuticals Inc. (MIST) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Press release · 1d ago
MILESTONE PHARMACEUTICALS INC: Q4 SHR LOSS $-0.19
Reuters · 1d ago
*Milestone Pharmaceuticals 4Q Loss $12.4M >MIST
Dow Jones · 1d ago
Press Release: Milestone Pharmaceuticals Reports -2-
Dow Jones · 1d ago
Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Dow Jones · 1d ago
Milestone Pharmaceuticals: Q4 Earnings Snapshot
Barchart · 1d ago
Weekly Report: what happened at MIST last week (0303-0307)?
Weekly Report · 4d ago
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule
TipRanks · 03/04 13:05
Weekly Report: what happened at MIST last week (0224-0228)?
Weekly Report · 03/03 09:02
TD Cowen Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)
TipRanks · 03/01 17:55
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)
TipRanks · 02/28 14:40
Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 02/28 14:36
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Benzinga · 02/28 14:26
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
TipRanks · 02/26 12:10
Milestone Pharmaceuticals Prepares for CARDAMYST Launch
TipRanks · 02/25 21:37
Weekly Report: what happened at MIST last week (0217-0221)?
Weekly Report · 02/24 09:02
Milestone Pharmaceuticals Receives Notice Of Allowance For New Patent Extending Etripamil's IP
NASDAQ · 02/19 17:54
Milestone receives notice of allawance from USPTO on etripamil nasal spray
TipRanks · 02/19 13:10
MILESTONE PHARMACEUTICALS INC: RECEIVES NOTICE OF ALLOWANCE ON NEW U.S. PATENT FOR ETRIPAMIL
Reuters · 02/19 13:08
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
More
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.